- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03344133
Effect of Exercise Programme on Gut Microbiota, CVD Risk Factors and Appetite Regulation in Overweight Women
Effect of a 4-week Moderate Intensity Exercise Programme on Gut Microbiota, Cardiovascular Disease Risk Factors and Appetite Regulation in Overweight Women
Studie Overzicht
Gedetailleerde beschrijving
Study Design: This is a randomized controlled study with a parallel design. Healthy, sedentary females aged between 18-45 years old will be recruited by means of an advertisement leaflet and word of mouth. Eligible participants will be enrolled in the study and will be randomly allocated to either exercise intervention (EX) or control (C) groups. The EX group will participate in a 4-week exercise intervention and the C group will be asked to continue with habitual life style for 4 weeks. Before and after 4 weeks of the intervention, participants from both groups will be asked to conduct a submaximal exercise test and a 7-hour experimental trial during which blood samples will be collected and metabolic rate will measured before and after consumption of standardized breakfast and lunch. Prior to the first 7-hour trial, participants will be asked to record diet for 3 days and replicate this diet prior to the second 7-hour trial. During these 3 days participants will provide fresh stool samples. Participants allocated to control group will have the option to participate in exercise intervention. A subset of the participants will repeat a 7-hour experimental trial and provide fresh stool and urine sample after 7 days of detraining.
Methods:
Preliminary Health Check: Participants will undertake a health screening questionnaire on the day of recruitment. Participants will also need to fill in Physical Activity Readiness Questionnaire (PARQ). Only participants who answered "no" to all questions in PARQ will conduct the submaximal exercise test.
Anthropometry: All participants will have height, weight and waist circumference measured at baseline and 4 weeks after the intervention.
7-hour Experimental Trial: Participants will attend the metabolic suite (New Lister Building, Glasgow Royal infirmary) in a fasted state at approximately 9.00 am. Participants will be instructed to lie supine on the couch, with the head resting on the pillow provided. Resting metabolic rate will be measured for 20 minutes and fasting blood sample will be obtained. A breakfast meal will be consumed immediately after the fasting sample and a lunch meal after 4 hours. Blood samples will be taken throughout a cannula hourly after breakfast and lunch consumption. Following each blood sample, metabolic rate will be measured for the duration of 20 minutes. Prior each blood sample, participants will fill in appetite questionnaires. Blood samples will be analysed for plasma lipids, glucose, insulin, inflammatory markers and gut appetite hormones using standard existing procedures.
Feacal sample collection & analysis: A disposable stool sample collection kit will be provided prior to the 7-hour trial day. Once collected, the container is sealed and placed in a larger sealable bag with a reducing sachet to remove oxygen and maintain anaerobic bacteria. Stool samples will be measured for changes in gut microbiota based on 16S rRNA amplicon sequencing, bacterial functional capacity and targeted bacterial metabolites (short chain fatty acids, sulphide, ammonia).
Exercise Training Programme: Exercise training will consist of 4 weekly sessions of endurance type exercise (cycling and running) lasting for 30, 40, 50, 60 minutes in the week 1, 2, 3 and 4 respectively. The time and day of each training trial will be agreed between the investigator and the participant and will be based around the participant's availability. All exercise sessions will be supervised by a researcher.
Submaximal Exercise Test: Participants will exercise on treadmill at gradually increasing intensities until 85% of maximal heart rate. During the last minute of each of the intensities heart rate will be measured and expired air will be collected by Douglas bag technique and analysed for oxygen consumption and carbon dioxide production. Relation between heart rate and rate of oxygen consumption will be used to predict maximal oxygen consumption, a marker of cardio-respiratory fitness.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Glasgow, Verenigd Koninkrijk, G312ER
- Werving
- School of Medicine, University of Glasgow / New Lister Building, Glasgow Royal Infirmary
-
Contact:
- Eleni Rizou, BSc MSc
- E-mail: e.rizou.1@research.gla.ac.uk
-
Contact:
- Konstantinos Gerasimidis, BSc MSc PhD
- E-mail: Konstantinos.Gerasimidis@glasgow.ac.uk
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Healthy, sedentary females, BMI>25 kg/m2, on a stable body weight for the last 3 months
Exclusion Criteria:
- Acute or chronic illness, use of antibiotics the past 3 months, smoking
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Exercise
4-week moderate intensity exercise programme
|
4-week moderate intensity exercise programme
|
|
Geen tussenkomst: Control
4 weeks of habitual life style
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Gut microbiota composition
Tijdsspanne: 12 months
|
Changes in the gut microbiota composition measured by 16S rRNA amplicon sequencing.
|
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Interleukin-6 (IL-6)
Tijdsspanne: 3 months
|
Changes in fasting and postprandial interleukin-6 pre- and post-interventions measured by Human IL-6 ELISA Ready-Set-Go (Affymetrix, eBioscience)
|
3 months
|
|
Glucose
Tijdsspanne: 3 months
|
Changes in fasting glucose pre- and post-interventions measured by Randox Glucose
|
3 months
|
|
Triglycerides
Tijdsspanne: 3 months
|
Changes in fasting and postprandial triglycerides pre- and post-interventions measured by Randox Triglycerides
|
3 months
|
|
Insulin
Tijdsspanne: 3 months
|
Changes in fasting insulin pre- and post-interventions measured by Mercodia Insulin ELISA
|
3 months
|
|
Peptide YY (PYY)
Tijdsspanne: 12 months
|
Changes in fasting and postprandial peptide YY pre- and post-interventions measured by Human PYY (Total) ELISA (Merc Millipore)
|
12 months
|
|
Glucagon-like peptide-1 (GLP-1)
Tijdsspanne: 12 months
|
Changes in fasting and postprandial glucagon-like peptide-1 pre- and post-interventions measured by GLP-1 Total ELISA (Merc Millipore)
|
12 months
|
|
Subjective appetite
Tijdsspanne: 12 months
|
Changes in subjective appetite (hunger, satiety, fullness, prospective food consumption, desire to eat) pre- and post-interventions measured by Visual Analogue Scales (VAS) where respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points (minimum score is 0 and maximum score is 100)
|
12 months
|
|
Faecal short-chain fatty acids
Tijdsspanne: 12 months
|
Changes in concentrations of feacal short-chain fatty acids pre- and post-interventions measured by TRACE 2000 Gas Chromatography (ThermoQuest Ltd)
|
12 months
|
|
Faecal pH
Tijdsspanne: 1 month
|
Changes in feacal pH between pre- and post-intervention measured by Hanna HI 98140
|
1 month
|
|
Body weight
Tijdsspanne: 1 month
|
Differences in body weight (kilograms) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Height
Tijdsspanne: 1 month
|
Height (meters) measured by stadiometer, a vertical ruler with a sliding horizontal paddle which is adjusted to rest on the top of the head
|
1 month
|
|
Body fat (kilograms)
Tijdsspanne: 1 month
|
Differences in body fat expressed in kilograms between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Body fat (% percentage)
Tijdsspanne: 1 month
|
Differences in body fat expressed as percentage (%) (proportion of fat to the total body weight) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Body Mass Index (BMI)
Tijdsspanne: 1 month
|
Differences in body mass index (weight and height will be combined to report BMI in kg/m^2) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Dietary Intake
Tijdsspanne: 6 months
|
Energy intake and macro nutrient intake using WinDiets software based on food composition tables
|
6 months
|
|
Maximum Oxygen Consumption
Tijdsspanne: 2 weeks
|
Maximum Oxygen Consumption (ml/kg/min) measured before and after the interventions by Servomex Gas Analyser
|
2 weeks
|
|
Energy substrate oxidation
Tijdsspanne: 6 months
|
Fat and carbohydrate oxidation in the fasted and postprandial state measured before and after the interventions using indirect calorimetry (Oxycon Pro)
|
6 months
|
|
Resting Metabolic Rate
Tijdsspanne: 2 month
|
Resting metabolic rate was measured before and after the interventions (Oxycon Pro)
|
2 month
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Konstantinos Gerasimidis, BSc MSc PhD, University of Glasgow
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 200140132
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Overgewicht en obesitas
-
University of Kansas Medical CenterBioNexus KC; Blue KC (Blue Cross Blue Shield)VoltooidZwangerschap gerelateerd | Prenatale zorg | Doula zorg | Black Maternal and Infant HealthVerenigde Staten
-
Swansea UniversityVoltooidA Bite of ACT' (BOA) Acceptance and Commitment Therapy Online cursus psycho-educatie | Een wachtlijstcontroleVerenigd Koninkrijk
-
University of SheffieldMid Yorkshire Hospitals NHS TrustIngetrokkenObesitas, Acceptance and Commitment Therapy, Weight Management ServiceVerenigd Koninkrijk
-
Bambino Gesù Hospital and Research InstituteVoltooidErnstige pediatrische obesitas (BMI > 97° pc -Volgens Centers for Disease Control and Prevention BMI Charts-) | Veranderde leverfunctietesten | Glykemische intolerantieItalië
-
Wenjie ZhengChildren's Hospital of Soochow University; Nanjing Children's Hospital; The First... en andere medewerkersNog niet aan het wervenPeriodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndroom
-
Alexandria UniversityVoltooidAcceptance and Commitment Therapy, geestelijke gezondheid, cognitieve stoornissen, colorectale kankerEgypte
-
University of PittsburghNational Institute on Aging (NIA)Nog niet aan het wervenDementie | Postoperatief delirium (POD) | Postoperatieve cognitieve achteruitgang | Perioperatieve complicaties | Postoperatieve neurocognitieve stoornis | Major Adverse Cardiac and Cerebrovascular EventsVerenigde Staten